Curriculum Vitae

DR. NUR FADHLINA BINTI ABDUL SATAR

Medical Lecturer
  • Dean Office
    Faculty of Medicine
  • nina.abdul
  • 0379493037

BIOGRAPHY

Dr Nur Fadhlina is an active member of Department of Clinical Oncology University Malaya, being awarded the Excellence Service Award in 2023 by University of Malaya. She completed MRCP(UK) and trained at University College London and Barts NHS Trusts. She subsequently obtained FRCR and Masters in Clinical Oncology under Institute Cancer Research London. She is passionate on issues pertaining to medical education and currently leads the Cancer ECHO UM project, collaborating with industry and cancer centres in Malaysia, running teaching sessions throughout the year. She was the Part 2 Program Coordinator of Master in Clinical Oncology UM from 2021-2023, responsible for coordination of teaching sessions and post graduate examination. She is co-supervisor for a PhD student, carrying out clinical trial in immunonutrition in Head and Neck cancer patients. She is also the Principal Investigator for industry led international clinical trials in Head and Neck and Breast cancers, winning CIC Award for Highest Research Grant procured in 2021. She has actively collaborated with local researchers and industry, publishing results in international journals such as Clinical Oncology, Frontiers in Nutrition and Diagnostics. She won the Japan Society Medical Oncology Rising Star in Asia Workshop Award, and presented work on nasopharyngeal cancer in Fukuoka, Japan in 2023. Dr Fadhlina speaks passionately on public forum, such as Breast Cancer Campaign launched by Breast Cancer Welfare Association 2023 and MOS Cancer Survivorship campaign 2024. She gave talks in ASCOMOS 2021, 2022 and is also the invited panellist for Global Oral Cancer Forum 2024.

ACADEMIC QUALIFICATION

  • MSC (ONCOLOGY), (Onkologi)
    University of London, UK
  • FRCR, (Radiologists)
    Royal College of Radiologist, London
  • MEMBERSHIP OF THE ROYAL COLLEGES OF PHYSICIANS
    Royal College of Physicians of Edinburgh, United Kingdom
  • MBBS, (Medicine and Surgery)
    University of Nottingham

MEMBERSHIPS

  • MEMBER, MEMBER
    2020 to present (International)
  • MALAYSIAN ONCOLOGY SOCIETY, MEMBER
    Since 2019 (National)
  • ROYAL COLLEGE OF RADIOLOGISTS, MEMBER
    2010 to 2023 (International)
  • ACADEMY OF MEDICINE MALAYSIA, MEMBER
    2021 to 2022 (National)
  • MEDICAL PROTECTION SOCIETY, MEMBER
    2018 to 2021 (National)
  • MALAYSIAN MEDICAL COUNCIL, REGISTERED MEMBER
    Since 2018 (University)
  • GENERAL MEDICAL COUNCIL UK, ACADEMIC MEMBER
    2006 to 2021 (International)

PUBLICATIONS

Article in Journal
WoS
  1. Satar, Nur Fadhlina Abdul; Hadi, Yusra; Wee, David Lee Dai; Shariff, Nisha Mohd; Ishak, Wan Zamaniah Wan (2023). Outcome for recurrent nasopharyngeal carcinoma in Malaysia: University Malaya Medical Centre, 2010-2019, ANNALS OF ONCOLOGY. 34, S1424-S1424. doi:10.1016/j.annonc.2023.09.265
  2. Song, Chin-Vern; van Gils, Carla H.; Yip, Cheng-Har; Soerjomataram, Isabelle; Taib, Nur Aishah Mohd; See, Mee-Hoong; Lim, Alexander; Satar, Nur Fadhlina Abdul; Bhoo-Pathy, Nirmala (2023). Discriminatory Ability and Clinical Utility of the AJCC7 and AJCC8 Staging Systems for Breast Cancer in a Middle-Income Setting, DIAGNOSTICS. 13(4). doi:10.3390/diagnostics13040674
  3. Ho, Gwo Fuang; Lee, Soo-Chin; Lim, Joanna; Bustam, Anita Zarina; Lim, Siew Eng; Saad, Marniza; Ow, Samuel Guan Wei; Ngoi, Natalie; Satar, Nur Fadhlina Abdul; Malik, Rozita Abdul; Alip, Adlinda; Law, Kian Boon; Toh, Yok Yong; Pan, Jia Wern; Teo, Soo Hwang (2022). A phase II, single-arm, open label, Simon two-stage study of pembrolizumab in patients with metastatic HER2-negative breast cancer: Evaluation of impact of germline variants in APOBEC3B (AUROR)., JOURNAL OF CLINICAL ONCOLOGY. 40(16)
  4. Tan, Sing Ean; Satar, Nur Fadhlina Abdul; Majid, Hazreen Abdul (2022). Effects of Immunonutrition in Head and Neck Cancer Patients Undergoing Cancer Treatment - A Systematic Review, FRONTIERS IN NUTRITION. 9. doi:10.3389/fnut.2022.821924
  5. Satar, N. Abdul; Lynch, S.; Wells, P.; Bowles, S.; Yip, K.; Conibear, J. (2017). Comparison of Dosimetric Parameters and Outcome in Non-Small Cell Lung Cancer Patients Having 3D Conformal or VMAT Plans, JOURNAL OF THORACIC ONCOLOGY. 12(11), S2038-S2038
  6. Satar, N. Abdul; Sibtain, A.; Cottrill, C.; Richards, T. M. (2017). Hypofractionated radiotherapy for inoperable rectal cancer: A retrospective analysis 2007 to 2015, RADIOTHERAPY AND ONCOLOGY. 123, S678-S678
  7. Yip, K.; Conibear, J.; Woolf, D.; Tarver, K.; Willis, B.; Hall, S.; Sun, F.; Kuhan, H.; Lambourne, B.; Piskilidis, P.; Kussaibati, R.; Martin, L.; Satar, N. Abdul; Gray, C. M. N.; Khan, A.; Doherty, G.; Prewett, S.; Smith, M.; Dancey, G.; Patterson, D. M.; Rimmer, Y.; Hollingdale, A.; Ingle, C.; Tasigiannopoulos, Z.; Aslam, S.; Waite, K.; Polychronis, A.; Ghafoor, Q.; Baijal, S.; Newsom-Davis, T.; Shah, R.; Forster, M.; Mulatero, C.; Greystoke, A.; Postmus, P. E.; Blackhall, F.; Gilligan, D. (2017). A retrospective multicentre audit of outcome among patients with anaplastic lymphoma kinase (ALK) gene rearrangement positive non-small cell lung cancer (NSCLC) who have been treated with crizotinib in England, LUNG CANCER. 103, S28-S29
  8. Abdul, N.; Ward, A.; Hawkesford, K. (2014). Acute Oncology Service and its Implications on Training: The Specialty Trainee's Perspective, CLINICAL ONCOLOGY. 26(3), 132-134. doi:10.1016/j.clon.2013.12.003
  9. Abdul, N.; Badreldin, W.; Robertson, A.; Dancey, G.; Khaira, M. (2013). Pragmatic approach to EGFR mutation testing in advanced lung cancer: a single institution's experience, LUNG CANCER. 79, S8-S8
Scopus
  1. Elias J.M., Satar N.F.A., Chean K.Y., Zaid R.M., Nasukhat N.A.M., Wahab D.A. (2022). Adjuvant breast radiotherapy outcome in older women: A Malaysian experience, The Medical journal of Malaysia. 77(1), 87-89
  2. Satar, N. F. A., Von, C. E., Yuin, J. L. P., & Ruey, N. M. (2020). A case of nasopharyngeal carcinoma and precious pregnancy. Medical Journal of Malaysia, 75(6), 738-741.
Others
  1. Jasmin Munchar, E., Abdul Satar, N. F., Vance Koi, Y. C., Rizma, M. Z., Nurul, A. M. N., & Abdul Wahab, D. (2022). Adjuvant breast radiotherapy outcome in older women: A Malaysian experience. The Medical Journal of Malaysia, 77(1), 87 89.
  2. N Abdul, A Ward, K Hawkesford. Acute Oncology Service and its Implications on Training: the Specialty Trainee's Perspective. Clinical Oncology, Volume 26, Issue 13, March 2014, pg 132-134 (WoS)
  3. Nina Abdul Satar, Rachel Lewis, Heather Payne. Hormone therapy in prostate cancer, Geriatric Medicine, 08, August 2013
  4. Rachel Lewis, Nina Abdul, Mary McCormack. Hormone therapy in breast cancer, Geriatric Medicine, 11, 2013.
Article in Proceeding
  1. A phase II, single-arm, open label, Simon two-stage study of pembrolizumab in patients with metastatic HER2-negative breast cancer: Evaluation of impact of germline variants in APOBEC3B (AUROR). Gwo Fuang Ho, Soo-Chin Lee, Joanna Lim, Anita Zarina Bustam, Siew Eng Lim, Marniza Saad, Samuel Guan Wei Ow, Natalie Ngoi, Nur Fadhlina Abdul Satar, Rozita Abdul Malik, Adlinda Alip, Kian Boon Law, Yok Yong Toh, Jia Wern Pan, and Soo Hwang Teo Journal of Clinical Oncology 2022 40:16_suppl, 1026-1026
Other Publications
  1. Abdul Satar NF, Razali K, Abdul Aziz AF, Pulse 2022, Digitalising Cancer Rehabilitation Care Through Industry Academia Partnership - Mass Media(Newspaper,Radio,Tv,Popular Magazine)
  2. Lead Authour for web based imaging learning module on Bladder Cancer for Clinical Oncology, Royal College of Radiologists' official website - submitted - Royal College Radiologists
  3. K Yip, J Conibear, D Woolf, K Tarver, C Mulatero, S Fei, N Abdul Satar et al. A retrospective multicentre audit of outcome among patients with anaplastic lymphoma kinase (ALK) gene rearrangement positive non-small cell lung cancer (NSCLC) who have been treated with crizotinib in England. Lung Cancer, January 2017 Volume 103, Supplement 1, Pages S28-29. - Extended Abstract
  4. Nina Abdul, Waleed Badreldin, Alexander Robertson, Gairin Dancey, Mandip Khaira. Pragmatic approach to EGFR mutation testing in advanced lung cancer: A single institution's experience. Lung Cancer (Impact Factor 4.294), Volume 79, S8 January 2013. - Extended Abstract
  5. N Abdul Satar, M McGregor, C Bebb, C Byrne, M Devoland, G McHaffie, S Roe, K Teahon. Defining the non surgical care pathway for patients with encapsulating peritoneal sclerosis, GUT journal (Impact factor 14.921) 2009; Vol 58(S1): PM211 - Extended Abstract

RESEARCH PROJECT

National
  1. 2022 - 2025, Others MOHE - Top 100 (IIRG)-HWB
    Wp1: Trigger Art-npc: Improving Nasopharyngeal Cancer (npc) Care Through Trigger-based Adaptive Radiotherapy ( Co-Researcher)
  2. 2022 - 2024, Government Agency - Manage by UMCARES
    Rebung 2.0: Smart Navigation Of The Early Cancer Diagnosis Care Pathway Extension Of Rebung Into Kg Cempaka & Seri Setia ( Co-Researcher)
  3. 2023 - 2024, Government Agency
    Rebung Multilevel, Integrated Cancer Early Diagnosis Health Literacy Initiative ( Co-Researcher)
  4. 2021 - 2022, Private Funding - Manage by UMCARES
    Cancer Multisectoral Collaboration Network In Implementing A Pilot Cancer Early Dectection Community Project To Reduce Breast And Other Cancers Early Diagnosis Barriers In The Urban B40 Group In Taman Medan Pj ( Co-Researcher)
  5. 2021 - 2028, Merck Sharp & Dohme (M) Sdn. Bhd.
    A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Pembrolizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy for the Treatment of Chemotherapy-Candidate Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (HR+/HER2-) Locally Recurrent Inoperable or Metastatic Breast Cancer (KEYNOTE-B49) ( Principal Investigator(PI))
  6. 2021 - 2026, Novartis Corporation (M) Sdn. Bhd.
    Happiness Registry: Living Well with Advanced Breast Cancer ( Co-Researcher)
  7. 2022 - 2024, Novartis Corporation (Malaysia) Sdn Bhd
    EPIK-B4: A Phase II, multicenter, randomized, open-label, active-controlled study to assess the safety and efficacy of dapagliflozin + metformin XR versus metformin XR during treatment with alpelisib (BYL719) in combination with fulvestrant in participants with HR+, HER2-, advanced Breast Cancer with a PIK3CA mutation following progression on/after endocrine-based therapy ( Co-Researcher)
  8. 2021 - 2023, Naluri Hidup Sdn. Bhd.
    The Feasibility and Preliminary Efficacy of a Locally Developed Digital Health Intervention in Improving Breast Cancer Survivors Quality of Life (QoL) ( Principal Investigator(PI))
  9. 2020 - 2021, Adipolabs Healthcare (M) Sdn. Bhd.
    Hyperthermia in treating patients with painful unresectable abdominal or pelvic malignancy. ( Co-Researcher)
Private
  1. 2023 - 2029, Roche (Malaysia) Sdn. Bhd.
    A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF INAVOLISIB PLUS PALBOCICLIB AND FULVESTRANT VERSUS PLACEBO PLUS PALBOCICLIB AND FULVESTRANT IN PATIENTS WITH PIK3CA-MUTANT, HORMONE RECEPTOR POSITIVE, HER2-NEGATIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER ( Co-Researcher)
  2. 2022 - 2027, Merck Sharpe & Dohme (Malaysia) Sdn Bhd
    A Study of Pembrolizumab (MK-3475) Plus Platinum and Gemcitabine as First Line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (PIPER) ( Co-Researcher)
  3. 2023 - 2027, Gilead Sciences, Inc.
    A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF SACITUZUMAB GOVITECAN VERSUS TREATMENT OF PHYSICIAN S CHOICE IN PATIENTS WITH PREVIOUSLY UNTREATED, LOCALLY ADVANCED, INOPERABLE OR METASTATIC TRIPLE-NEGATIVE BREAST CANCER WHOSE TUMORS DO NOT EXPRESS PD-L1 OR IN PATIENTS PREVIOUSLY TREATED WITH ANTI-PD-(L)1 AGENTS IN THE EARLY SETTING WHOSE TUMORS DO EXPRESS PD-L1 ( Co-Researcher)
  4. 2023 - 2027, Gilead Sciences, Inc.
    A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF SACITUZUMAB GOVITECAN AND PEMBROLIZUMAB VERSUS TREATMENT OF PHYSICIANS CHOICE AND PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED, LOCALLY ADVANCED INOPERABLE OR METASTATIC TRIPLE-NEGATIVE BREAST CANCER, WHOSE TUMORS EXPRESS PD-L1 ( Co-Researcher)
  5. 2023 - 2025, BEIGENE SINGAPORE PTE. LTD.
    PHASE 1 STUDY INVESTIGATING THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PRELIMINARY ANTITUMOR ACTIVITY OF THE ANTI OX40 AGONIST MONOCLONAL ANTIBODY BGB-A445 IN COMBINATION WITH THE ANTI-PD-1 MONOCLONAL ANTIBODY TISLELIZUMAB IN PATIENTS WITH ADVANCED SOLID TUMORS ( Co-Researcher)
  6. 2022 - 2024, Private Funding
    Research And Educational Activities To Increase Vaccination Awareness In Malaysia ( Co-Researcher)
  7. 2021 - 2023, Private Funding
    The Feasibility and Preliminary Efficacy of a Locally Developed Digital Health Intervention In Improving Breast Cancer Survivors' Quality of Life (QoL) ( Principal Investigator(PI))
International
  1. 2022 - 2027, Astrazeneca Sdn. Bhd.
    A phase III, Randomized, Open-Label, Sponsor-Blinded, Multicenter Study of Durvalumab in Combination with Tremelimumab Lenvatinib Given Concurrently with Transarterial Chemoembolization (TACE) Compared to TACE Alone in Patients with Locoregional Hepatocellular Carcinoma (EMERALD-3) ( Co-Researcher)
  2. 2023 - 2026, University College London
    ARCHERY: ARTIFICIAL INTELLIGENCE BASED RADIOTHERAPY TREATMENT PLANNING FOR CERVICAL AND HEAD AND NECK CANCER ( Co-Researcher)
  3. 2010 - 2026, NCC Singapore
    ASCOLT Aspirin in treating patients with Dukes stage C colon or rectal cancer, or high risk Dukes stage B colon cancer that has been completely removed by surgery. ( Consultant)
  4. 2022 - 2025, Novotech Clinical Research (M) Sdn Bhd
    An Open-Label, Multicenter Phase 1b/2 Study of Nanatinostat and Valganciclovir in Patients with Advanced Epstein-Barr VirusPositive (EBV+) Solid Tumors and in Combination with Pembrolizumab in Patients with Recurrent/Metastatic Nasopharyngeal Carcinoma ( Principal Investigator(PI))
  5. 2022 - 2024, Boehringer Ingelheim Malaysia Sdn Bhd
    AN OPEN LABEL TRIAL OF BI 765063 IN COMBINATION WITH BI 754091 (EZABENLIMAB) ALONE OR WITH BI 836880, CHEMOTHERAPY, OR CETUXIMAB, IN PATIENTS WITH RECURRENT/METASTATIC HEAD AND NECK SQUAMOUS CELL CARCINOMA (HNSCC) OR HEPATOCELLULAR CARCINOMA (HCC) ( Co-Researcher)
  6. 2019 - 2024, Private Funding
    A Phase 3, Global, Multi-Center, Double-Blind, Randomized, Efficacy Study of Zolbetuximab (IMAB362) Plus CAPOX Compared with Placebo Plus CAPOX as First-line Treatment of Subjects with Claudin (CLDN) 18.2-Positive, HER2-Negative, Locally Advanced Unresectable or Metastatic Gastric or Gastrosophageal Junction (GEJ) Adenocarcinoma. ( Consultant)
  7. 2020 - 2024, Private Funding
    A Phase III, Randomized, Double-Blind, Clinical Trial of Pembrolizumab (MK-3475) Plus Chemotherapy (XP or FP) Versus Placebo Plus Chemotherapy (XP or FP) as Neoadjuvant/Adjuvant Treatment for Subjects With Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma (KEYNOTE-585) ( Consultant)
  8. 2019 - 2023, Kura Oncology, Inc.
    A Pivotal Study of Tipifarnib in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) with HRAS mutations who have Received At least One Prior Line of Therapy ( Principal Investigator(PI))
  9. 2020 - 2022, Private Funding
    AUROR: Study of Pembrolizumab in Metastatic Her 2 negative in Breast Cancer patients with APOBEC3B mutation ( Consultant)
  10. 2020 - 2022, International Funding
    COVID-19 in patients with cancer: first report of the ESMO international, registry-based, cohort study (ESMO-CoCARE), European Society for Medical Oncology (ESMO) ( Co-Researcher)
  11. 2019 - 2021, International Funding
    KO-TIP-007: The AIM-HN and SEQ-HN Study: A 2 Cohort, Non-comparative, Pivotal Study Evaluating the Efficacy of Tipifarnib in Patients with Head and Neck Squamous Cell Carcinoma (HNSCC) with HRAS Mutations (AIM-HN) and the Impact of HRAS Mutations on Response to First Line Systemic Therapies for HNSCC (SEQ-HN). ( Principal Investigator(PI))
  12. 2019 - 2021, International Funding
    GLOW: A Phase 3, Global, Multi-Center, Double-Blind, Randomized, Efficacy Study of Zolbetuximab (IMAB362) Plus CAPOX Compared with Placebo Plus CAPOX as First-line Treatment of Subjects with Claudin (CLDN) 18.2-Positive, HER2-Negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma ( Consultant)
  13. 2019 - 2021, MSD LTD
    MK3475-966 Pembrolizumab or Placebo Plus Gemcitabine/Cisplatin for FirstLine Advanced and/or Unresectable Biliary Tract Carcinoma (KEYNOTE-966) ( Consultant)
  14. 2018 - 2021, Private Funding
    A Randomized, Double-Blind, Placebo-Controlled Phase III Clinical Trial of Pembrolizumab (MK-3475) in Combination with Cisplatin and 5-Fluorouracil versus Placebo in Combination with Cisplatin and 5-Fluorouracil as First-Line Treatment in Subjects with Advanced/Metastatic Esophageal Carcinoma (KEYNOTE-590) ( Consultant)
  15. 2020 - 2021, Private Funding
    A Long-term Follow-up Study for Cardiac Safety in the Patients with HER2 Positive Early or Locally Advanced Breast Cancer Who Have Completed the SB3-G31-BC (Samsung Bioepis) ( Consultant)
  16. 2020 - 2021, NONE
    ESMO Co Care - ESMO Covid 19 Cancer Registry (International) ( Principal Investigator(PI))

CONSULTANCY PROJECT

  • Roche Early Breast Cancer Advisory Board, Roche
    01 Apr 2021 - 01 Apr 2021 (National)
  • Expert Meeting Differentiated Thyroid Cancer, Eisai
    01 Apr 2021 - 01 Apr 2021 (National)
  • Developing An Intervention Decision Aid for Patients With Metastatic Breast Cancer: Evaluating The Acceptability of Decision Aid Among Healthcare Professionals, UMMC
    01 Apr 2020 - 01 Apr 2021 (National)
  • Frcr Part 2 Course, Christie Cancer Research Centre
    01 Dec 2019 - 01 Dec 2020 (International)
  • Rebung: Cancer Module Development Workshop, University Malaya
    01 Nov 2020 - 01 Nov 2020 (National)
  • Masterclass in Systemic Cancer Therapy, Clinical oncology department
    01 Nov 2020 - 01 Nov 2020 (National)
  • Advice On Product Registration, from Drug Control Authority, Ministry of Health, Drug Control Authority
    01 Jan 2020 - 01 Jan 2020 (National)
  • Masterclass in Systemic Cancer Therapy 2019, UM
    01 Dec 2019 - 01 Dec 2019 (National)
  • Reviewed Article On Prostate Cancer for British Journal of Urology International (Bjui) Knowledge September 2016,  British Journal of Urology International (
    01 Apr 2016 - 01 Apr 2016 (International)
  • Reviewed Article On Acute Oncology Service for Royal College Radiologists' Journal, Clinical Oncology, October 2016, Clinical Oncology Journal
    01 Apr 2016 - 01 Apr 2016 (International)

SOCIAL RESPONSIBILITY ACTIVITIES

  • Panel of Speakers for Breast Cancer Awareness in This Year&Rsquo;S Pinktober Campaign by Talkhealthasia.Com in Partnership With Breast Cancer Welfare Association (Bcwa) - Launch of Breast Cancer Campaign, (26 Aug 2023 - 26 Aug 2023) (National)
  • Participated in Powerman Duathlon, (18 Jun 2023 - 18 Jun 2023) (National)
  • Organising Committee - Colorectal Cancer Awareness Virtual Run 2022 is The First Running Event Organised Jointly by The Clinical Oncology Department (University of Malaya), Colorectal Surgery Division (Dept of Surgery - UM) and The Malaysian Society of Colorectal Surgeons. This Event Aims to Raise Awareness About Colorectal Cancer in Malaysia., (04 Mar 2022 - 31 Mar 2022) (National)
  • Organising Committee and Invited Speaker for "Exercise and Cancer", (19 Feb 2022 - 19 Feb 2022) (National)
  • 80km Running Challenge in June 2021 to Fundraise for Sabah Citizens. Raised Rm45,000, Working Together in Spartanmomcrew Community Society., (01 Jun 2021 - 30 Jun 2021) (National)
  • Committee Member of Virtual Aerobicton for Cancer Survivors, (27 Feb 2021 - 27 Feb 2021) (University)
  • Raising Funds for Orang Asli Welfare by Participating in Viper Genitng 2020, (08 Mar 2020 - 08 Mar 2020)
  • Raised Rm10,000 in Aid of Refugee'S Medical Aid Fund (Al Ikhlas Society) - Completed Obstacle Course Race in Raising Fund, (07 Dec 2019 - 07 Dec 2019)